0800 Immune

0800 466 863

Zostavax resources for health professionals

Who can receive funded Zostavax®?

Standard programme

  • Adults aged 65 years

Catch-up programme EXTENDED TO 31 December 2021

  • Adults aged 66–80 years

Zostavax and annual influenza vaccination

  • Annual influenza immunisation is recommended and funded for adults aged 65 years or over.
  • One Zostavax is recommended for adults aged 65 years to under 80 years. This dose is also funded.
    • Zostavax and influenza vaccine can be administered at the same visit.
    • Zostavax is only given as a single dose – it IS NOT administered every year that an eligible adult receives their influenza vaccination.
  • When Zostavax and an influenza vaccination are administered to an eligible adult at the same visit from 1 April through 31 December:
    • The ability to claim an additional payment of $15 for administering Zostavax and influenza vaccines at the same visit that was introduced from 4 June 2018 will continue in 2019. Please contact your PHO on how to claim for these events.

Hormonal cancer treatments and Zostavax

The following hormonal cancer treatments do not cause immunosuppression:

Trade – Generic name

Generic – Trade name

Arimidex – Anastrazole Anastrazole – Arimidex
Bicalox – Bicalutamide Bicalutamide – Bicalox
Mestane – Exemestane Cyproterone – Procur, Siterone
Letara – Letrozole Exemestane – Mestane
Letrole – Letrozole Goserelin – Zolodex
Procur – Cyproterone Letrozole – Letara, Letrole
Siterone – Cyproterone Tamoxifen – Tamoxifen
Tamoxifen – Tamoxifen  
Zolodex – Goserelin  

Resource links

  Checklist for the shingles vaccines (Zostavax®) for patients

  Screening tool for the HZV (shingles) vaccine (Zostavax®) for health professionals

 

  Diseases and medications when live vaccines may be contraindicated

  Quick answers to frequent Zostavax® questions – November 2020

  Immunisation Handbook 2020

  • Chapter 4 Immunisation of special groups

    • Section 4.3.3 Primary immune deficiencies
    • Section 4.3.4 Secondary (acquired) immune deficiences
      • Section 4.3.5 Individuals receiving corticosteroids
        • Table 4.1 Guidelines for live virus vaccine administration for individuals receiving corticosteroid agents
      • Section 4.3.6 Individuals receiving non-corticosteroid immunomodulatory agents
        • Table 4.2 Guidelines for live virus vaccine administration for individuals receiving non-corticosteroid agents
  • Chapter 22 Zoster (herpes zoster/shingles)

    • Section 22.5 Recommended immunisation schedule
      • Table 22.1 Herpes zoster vaccine (ZV) recommendations
    • Section 22.5.2 Other considerations
      • Vaccination of individuals aged 50–64 years (unfunded)
      • Individuals with a history of zoster (shingles)
      • Household contacts of immunocompromised individuals
      • Serological testing
    • Section 22.6 Contraindications and precautions
      • Section 22.6.1 Contraindications
      • Section 22.6.2 Precautions

  HealthEd 

  Immunisation for older people 2020 (HE2540)

  Immunisation for older people in te reo Māori 2020 (HE2541)

  HealthEd

  Immunisation for older people - Large print 2020 (HE2548)

  HealthEd

  After your immunisation Information for teenagers and adults following immunisation (HE2505)

  Prevention of herpes zoster (shingles) through immunisation

 

   Herpes zoster (shingles)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Last updated: Nov 2020